Clinical trial
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis
NCT05130970 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- CSL Behring
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 3, 2022
- Completion date
- January 2, 2024
- Enrollment
- 81 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.